Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
S 1884 (School Access to Emergency Epinephrine); HR 6433 FDA User Fee Correction Act; Patent settlements; Serialization; Issues related to HIV/AIDS: Funding for antiretrovirals, PEPFAR, Global Fund, FDA; Issues related to biogenerics; Issues related to the generic drug industry
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2012 · second_quarter · 2A
S. 3187 - Food and Drug Administration Safety and Innovation Act; S. 1884 - School Access to Emergency Epinephrine Act; Drug shortages; Patent settlements; Serialization; Issues related to HIV/AIDS; Funding for antiretrovirals, PEPFAR, Global Fund, FDA; Issues relating to biogenerics; Issues relating to the generic drug industry; Issues relating to Average Manufacturer Price (AMP)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Source: Senate LDA
2012 · third_quarter · Q3
S 1884 (School Access to Emergency Epinephrine); HR 6433 FDA User Fee Correction Act; Patent settlements; Serialization; Issues related to HIV/AIDS: Funding for antiretrovirals, PEPFAR, Global Fund, FDA; Issues related to biogenerics; Issues related to the generic drug industry
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2012 · second_quarter · Q2
S. 3187 - Food and Drug Administration Safety and Innovation Act; S. 1884 - School Access to Emergency Epinephrine Act; Drug shortages; Patent settlements; Serialization; Issues related to HIV/AIDS; Funding for antiretrovirals, PEPFAR, Global Fund, FDA; Issues relating to biogenerics; Issues relating to the generic drug industry; Issues relating to Average Manufacturer Price (AMP)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2012 · first_quarter · Q1
User Fees; Drug Shortages; Patent Settlements; Food, Drug, and Cosmetic Act (FDCA); Globalizing the FDA; Serialization; Access to epinephrine auto-injectors in an emergency; Issues relating to HIV/AIDS, funding for Antiretrovirals (ARVs), PEPFAR, Global Fund; Issues relating to biosimilars; Issues relating to the generic drug industry; Issues relating to Average Manufacturer Price (AMP)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2011 · fourth_quarter · Q4
Medicaid reimbursement
Authorized Generics; User Fees; Drug Shortages; Patent Settlements; Food, Drug, and Cosmetic Act (FDCA); Serialization; Access to epinephrine auto-injectors in an emergency; Issues relating to HIV/AIDS, funding for Antiretrovirals (ARVs), PEPFAR, Global Fund; Issues relating to biosimilars; Issues related to the generic drug industry; Issues related to Average Manufacturer Price (AMP); Globalizing the FDA
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2011 · third_quarter · Q3
S.1356 Medicaid
Authorized Generics, User Fees, Affordable Medicines Act, HR1249 The America Invents Act, Drug Safety, Drug Shortage, Food, Drug and Cosmetic Act, FDA, Issues related to Generic Drug Industry, Issues related to funding for Antiretrovirals (ARVs), PEPFAR, Global Fund, Serialization, Biosimilars
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)